Vertex Pharmaceuticals Incorporated vs Vistra Corp — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B), while Vistra Corp trades at $162.33 (market cap $53.27B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.3× Vistra Corp's market cap, and Vistra Corp pays a 0.58% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRTX | VST | |
|---|---|---|
Market Cap | $121.95B | $53.27B |
Sector | Health | Technology |
52-Week High | $529.59 | $217.92 |
52-Week Low | $366.54 | $134.71 |
Enterprise Value | $116.69B | $75.03B |
Dividend Yield | — | 0.58% |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →